Disclosed herein is a pharmaceutical combination or composition, comprising of selective estrogen receptor modulator(s) in combination with selective serotonin reuptake inhibitor(s) and dopamine (D2) receptor agonists in the treatment and/or management of seizures and/or convulsions and/or epilepsies and/or neurodegeneration with or without associated neurological (Depression, Obsessive Compulsive Disorders, Parkinsonism e.t.c) and endocrine disorders (Osteoporosis). Further the present invention also discloses a preferable synergistic combination of Raloxifene with Fluoxetine and Bromocriptine in the treatment and/or management of above mentioned disorders and/or disease states in particular generalized seizures and/or generalized seizures with associated neurological disorders. Preferred formulations include tablets, capsules, suspensions, emulsions, injectables, ointments, creams and other suitable formulations as may be deemed necessary.
